Morgan Stanley lowered the firm’s price target on 2seventy Bio to $7 from $13 and keeps an Equal Weight rating on the shares. The firm introduced a 70% probability-of-success for Abecma commercialization in the 3L setting, which contributes to a decrease in its U.S. Abecma peak sales projections from ~$750M to ~$600M, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TSVT:
- Bristol Myers, 2seventy Bio announce result from KarMMa-3 Ph3 trial of Abecma
- Engine Capital sends letter to 2seventy’s board to ‘maximize’ shareholder value
- 2seventy Bio downgraded to Neutral at Wedbush after FDA panel announcement
- Bristol Myers Squibb (NYSE:BMY) Falls after FDA Delays Action on Cancer Therapy
- 2seventy Bio downgraded to Neutral from Outperform at Wedbush
